3.2 MR estimates for the causal effects of BW on cancer risk.
The result of the IVW showed us that high BW can reduce the risk of
invasive mucinous ovarian cancer (OR: 0.62; 95%CI: 0.39-0.97). However,
the relationship between BW and ovarian cancer overall or endometrioid
ovarian cancer was not significant (OR: 0.97; 95%CI: 0.69-1.38). Other
cancers subsumed in our study were found to be unrelated to BW,
including Lung cancer overall (OR:1.31; 95%CI: 0.92-1.69), Lung
adenocarcinoma (OR: 1.14; 95%CI: 0.92-1.36); Squamous cell lung cancer
(OR: 1.01; 95%CI: 0.72-1.30), Breast cancer overall (OR: 0.94; 95%CI:
0.80-1.11), ER-positive breast cancer (OR: 0.95; 95%CI: 0.80-1.11),
ER-negative breast cancer (OR: 0.95; 95%CI: 0.76-1.17), Colorectal
cancer(OR: 1.00; 95%CI: 0.99-1.00), Endometrial (OR: 0.99; 95%CI:
0.99-1.00), Malignant melanoma (OR: 1.00; 95%CI: 1.00-1.00), Prostate
cancer(OR: 0.99; 95%CI: 0.98-1.01). (Table 2)
All types of cancers were tested for heterogeneity and pleiotropy
analysis to ensure the reliability of our results. The MR-Egger
regression is very close to 0 (p>0.05) and the results of
MR-PRESSO were not statistically significant (p>0.05) which
indicated that there was weak horizontal pleiotropy between BW and
cancers. Besides, our outcomes of the Q test (p<0.05) and
I2 test (I2<25%)
illustrated that the existence of heterogeneity is insignificant. And
the leave-one-out sensitivity analysis showed that the effect of each
SNP on the results was consistent. (Table S13 - Table S14, Figure S26-
Figure S38)